{
  "docId": "019de512-188f-75bd-b9c3-b699923bd74c",
  "docSlug": "b87a8eceb8fdc0b05f41052c19d68b16",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 19,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 56,
  "notes": "The table uses a color-coded heatmap where red indicates higher potency (lower IC50 values) and yellow/white indicates lower potency. Includes disclaimers about lack of head-to-head trials.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de512-188f-75bd-b9c3-b699923bd74c/14",
  "deckHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c",
  "deckJsonHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c.json",
  "deckAnchorHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.17,
        "x": 0.709,
        "y": 0.68
      },
      "kind": "callout",
      "text": "EUA: 300mg IM, Prevention",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a014922-2764-4cbf-81a1-04ac0052aa8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.17,
        "x": 0.709,
        "y": 0.27
      },
      "kind": "callout",
      "text": "Ph3: 300mg IM, Prevention, Treatment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d2773ce-3794-48f0-9a5c-49f3fbf33d39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.17,
        "x": 0.709,
        "y": 0.33
      },
      "kind": "callout",
      "text": "EUA: 500mg IV, Treatment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfdcdd71-f705-47cc-be4c-414b15097309",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "There are no head-to-head trials between ADG20 and the other products referenced on this slide. No comparisons can be made between product efficacy or safety.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d709cab1-446a-4166-a463-d24e82f06d79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.15,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": "Company logos for ADG20, GSK/VIR, Regeneron, Lilly, AstraZeneca",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f790f99c-aeb2-48fd-bef7-f7eba96f8a05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.25,
        "y": 0.2
      },
      "kind": "table",
      "text": "Heatmap matrix of antibody neutralization values across variants",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecb1fabe-28c6-46cb-9724-5e16da97820b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.15,
        "y": 0.1
      },
      "kind": "title",
      "text": "ADG20 shows broad yet variable neutralizing activity against all variants of concern",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f0daf5d-f21c-4e15-9636-73b0521d7680",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "In vitro neutralization of antibodies in clinical development versus variants of concern",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21f078e1-ae69-4e7c-9a16-e3589795e060",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Heatmap matrix",
      "slug": "heatmap-matrix",
      "agent": null,
      "layer": "slide",
      "matchId": "572229a6-6ea0-498b-9c98-a842cd37f27b",
      "evidence": "Heatmap matrix of antibody neutralization values across variants",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "heatmap-matrix",
      "slug": null,
      "matchId": "c2af1c32-a0a5-4201-a72d-77ce9b621db5",
      "evidence": "The slide uses a color-coded matrix to compare quantitative data across two dimensions (antibodies vs variants).",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 5,
      "beatId": "6a1a205b-c7b3-4004-94f2-1eab1f50d86f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problem through multiple tables and data points, highlighting the challenge of COVID-19 variants.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "367a8c0e-d39d-4694-aace-945e8b5a0e36",
      "evidence": "The document implies the cost of inaction through its emphasis on the challenge of COVID-19 variants and the need for effective treatments.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing COVID-19 variants?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}